Golimumab is a human IgG monoclonal antibody specific for human tumor necrosis 
factor alpha. Golimumab has been approved for use in rheumatological conditions; 
however, its use in inflammatory bowel disease is still being evaluated in 
clinical trials. We report a case of an exacerbation of ulcerative proctitis 
after starting on golimumab for ankylosing spondylitis.